Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRCT NASDAQ:IVA NASDAQ:SLGL NASDAQ:TRAW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRCTDirect Digital$2.80-1.1%$3.23$2.17▼$172.70$2.08M5.33459,488 shs4,483 shsIVAInventiva$3.51-5.5%$4.81$2.85▼$7.98$727.81M0.68503,940 shs509,067 shsSLGLSol-Gel Technologies$73.42+3.0%$73.01$6.96▼$97.97$206.30M1.1335,094 shs42,297 shsTRAWTraws Pharma$0.84+0.1%$1.39$0.64▼$3.27$8.51M1.451.32 million shs76,647 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRCTDirect Digital+1.80%-3.74%-17.49%-10.44%-97.57%IVAInventiva+5.70%+3.63%-26.82%-38.37%+11.11%SLGLSol-Gel Technologies-3.44%-2.21%-7.13%-9.88%+874.03%TRAWTraws Pharma-6.09%+0.20%-43.79%-58.13%-45.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRCTDirect Digital$2.80-1.1%$3.23$2.17▼$172.70$2.08M5.33459,488 shs4,483 shsIVAInventiva$3.51-5.5%$4.81$2.85▼$7.98$727.81M0.68503,940 shs509,067 shsSLGLSol-Gel Technologies$73.42+3.0%$73.01$6.96▼$97.97$206.30M1.1335,094 shs42,297 shsTRAWTraws Pharma$0.84+0.1%$1.39$0.64▼$3.27$8.51M1.451.32 million shs76,647 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRCTDirect Digital+1.80%-3.74%-17.49%-10.44%-97.57%IVAInventiva+5.70%+3.63%-26.82%-38.37%+11.11%SLGLSol-Gel Technologies-3.44%-2.21%-7.13%-9.88%+874.03%TRAWTraws Pharma-6.09%+0.20%-43.79%-58.13%-45.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRCTDirect Digital 1.50ReduceN/AN/AIVAInventiva 3.10Buy$16.56372.34% UpsideSLGLSol-Gel Technologies 2.67Moderate Buy$197.50169.01% UpsideTRAWTraws Pharma 1.60Reduce$1.0019.33% UpsideCurrent Analyst Ratings BreakdownLatest SLGL, DRCT, TRAW, and IVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026SLGLSol-Gel Technologies MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$285.006/18/2026TRAWTraws Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Negative$1.006/18/2026TRAWTraws Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$1.006/15/2026TRAWTraws Pharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral6/15/2026TRAWTraws Pharma LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral6/4/2026SLGLSol-Gel Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D-)5/29/2026TRAWTraws Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (E+)5/29/2026SLGLSol-Gel Technologies TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/22/2026SLGLSol-Gel Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Sell (D+)5/20/2026TRAWTraws Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.005/15/2026TRAWTraws Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRCTDirect Digital$33.22M0.06N/AN/A($18.82) per share-0.15IVAInventiva$4.48M162.39N/AN/A($0.22) per share-15.93SLGLSol-Gel Technologies$19.39M10.64N/AN/A$8.19 per share8.96TRAWTraws Pharma$2.79M3.05$0.72 per share1.17($0.07) per share-11.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRCTDirect Digital-$18.95M-$201.62N/AN/AN/A-65.75%N/A-59.57%8/4/2026 (Estimated)IVAInventiva-$400.67MN/AN/AN/AN/AN/AN/AN/AN/ASLGLSol-Gel Technologies-$6.13M-$0.34N/AN/AN/A-5.66%-3.17%-2.58%8/21/2026 (Estimated)TRAWTraws Pharma$9.17M-$1.69N/AN/AN/AN/A-913.18%-133.88%8/13/2026 (Estimated)Latest SLGL, DRCT, TRAW, and IVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/28/2026Q1 2026SLGLSol-Gel Technologies-$2.86-$1.31+$1.55$1.31$0.90 million$0.11 million5/15/2026Q4 2025TRAWTraws Pharma-$0.92-$0.53+$0.39-$0.53$2.72 millionN/A5/11/2026Q4 2025DRCTDirect Digital-$7.74-$7.25+$0.49-$10.32$6.82 million$6.68 million4/15/2026Q4 2025TRAWTraws Pharma-$1.2238-$0.71+$0.5138-$0.71$0.06 millionN/A3/30/2026Q4 2025IVAInventiva-$0.18-$0.7480-$0.5680-$0.16$8.67 million$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDRCTDirect DigitalN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ATRAWTraws PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRCTDirect DigitalN/A0.160.16IVAInventivaN/A3.163.16SLGLSol-Gel TechnologiesN/A8.848.84TRAWTraws PharmaN/A0.430.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRCTDirect Digital4.02%IVAInventiva19.06%SLGLSol-Gel Technologies26.18%TRAWTraws Pharma7.95%Insider OwnershipCompanyInsider OwnershipDRCTDirect Digital25.57%IVAInventiva32.00%SLGLSol-Gel Technologies66.51%TRAWTraws Pharma7.57%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRCTDirect Digital60743,000553,000Not OptionableIVAInventiva100207.71 million141.24 millionNot OptionableSLGLSol-Gel Technologies502.81 million941,000No DataTRAWTraws Pharma1710.16 million9.39 millionNo DataSLGL, DRCT, TRAW, and IVA HeadlinesRecent News About These CompaniesTraws Pharma Provides Updated Guidance on Influenza Prophylaxis ProgramJune 22 at 7:00 AM | globenewswire.comQ2 EPS Estimates for Traws Pharma Lifted by HC WainwrightJune 22 at 1:12 AM | americanbankingnews.comBrokerages Set Traws Pharma, Inc. (NASDAQ:TRAW) Target Price at $8.00June 20, 2026 | americanbankingnews.comOutlook for Bucks County biotech take another hit with second setback for flu drugJune 15, 2026 | bizjournals.comTraws defers midphase flu study after negative regulatory reviewJune 15, 2026 | fiercebiotech.comFMicron, Nebius surge premarket; Traws Pharma tumblesJune 15, 2026 | finance.yahoo.comTraws Pharma shares slide after UK regulator postpones influenza studyJune 15, 2026 | msn.comTraws Pharma (NASDAQ:TRAW) Raised to Sell at Wall Street ZenJune 13, 2026 | americanbankingnews.comWhy did TRAW stock slump 28% after hours?June 13, 2026 | msn.comTraws Pharma Defers Phase 2a Study of Tivoxavir Marboxil Following UK Regulatory ReviewJune 12, 2026 | quiverquant.comQTraws Pharma Provides Regulatory Update on Influenza ProgramJune 12, 2026 | globenewswire.comTraws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease OutbreaksMay 27, 2026 | globenewswire.comTraws Pharma Updates ATM Equity Offering Prospectus SupplementsMay 26, 2026 | tipranks.comTraws Pharma Provides Business Highlights and Reports Q1 2026 Financial ResultsMay 15, 2026 | globenewswire.comTraws Pops on Hantavirus ResearchMay 9, 2026 | baystreet.caA hantavirus update has sent this nano-cap biotech stock surging today – here’s why retail sees potential 20x gainsMay 9, 2026 | msn.comTraws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship OutbreakMay 8, 2026 | benzinga.comTraws Pharma Advances Development of Clinical Candidates for Hantavirus TreatmentMay 8, 2026 | quiverquant.comQTraws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus InfectionsMay 8, 2026 | globenewswire.comTraws Pharma (TRAW) price target decreased by 24.14% to 5.61April 29, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLGL, DRCT, TRAW, and IVA Company DescriptionsDirect Digital NASDAQ:DRCT$2.80 -0.03 (-1.06%) As of 01:58 PM Eastern This is a fair market value price provided by Massive. Learn more.Direct Digital Holdings, Inc. operates as an end-to-end full-service programmatic advertising platform. The company's platform primarily focuses on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy- and sell-side of the digital advertising ecosystem. It serves various industry verticals, such as travel, healthcare, education, financial services, consumer products, and other sectors with a focus on small and mid-sized businesses. The company was founded in 2018 and is headquartered in Houston, Texas.Inventiva NASDAQ:IVA$3.50 -0.21 (-5.53%) As of 02:07 PM Eastern This is a fair market value price provided by Massive. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Sol-Gel Technologies NASDAQ:SLGL$73.42 +2.16 (+3.03%) As of 01:58 PM Eastern This is a fair market value price provided by Massive. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.Traws Pharma NASDAQ:TRAW$0.84 +0.00 (+0.06%) As of 02:07 PM Eastern This is a fair market value price provided by Massive. Learn more.Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
